Pridopidine, a dopamine stabilizer that is a D2 receptor antagonist and agonistically affects Sigma1R [345,362,363], is included in phase 3 clinical trials for patients with early stage HD (NCT04556656) and phase 2/3 for participants with ALS (NCT04615923). The gene discussed is SIGMAR1; the disease is amyotrophic lateral sclerosis.